

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/005898 A1

(51) International Patent Classification:

A61P 9/00 (2006.01) C07D 498/14 (2006.01)
A61P 25/00 (2006.01) C07D 513/04 (2006.01)
A61P 29/00 (2006.01) C07D 513/14 (2006.01)
A61P 37/00 (2006.01) A61K 31/55 (2006.01)
C07D 487/04 (2006.01) A61K 31/553 (2006.01)
C07D 498/04 (2006.01) A61K 31/554 (2006.01)

(21) International Application Number:

PCT/US2021/039112

(22) International Filing Date:

25 June 2021 (25.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/047,194 01 July 2020 (01.07.2020) US

(71) Applicant: RIGEL PHARMACEUTICALS, INC.

[US/US]; 1180 Veterans Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: BHAMIDIPATI, Somasekhar; c/o Rigel Phar-

maceuticals, Inc., 1180 Veterans Boulevard, South San
Francisco, California 94080 (US). DARWISH, Ihab; c/
o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard,
South San Francisco, California 94080 (US). IRVING,
Mark; c/o Rigel Pharmaceuticals, Inc., 1180 Veterans
Boulevard, South San Francisco, California 94080 (US).
KOLLURI, Rao; c/o Rigel Pharmaceuticals, Inc., 1180
Veterans Boulevard, South San Francisco, California 94080
(US). MASUDA, Esteban; c/o Rigel Pharmaceuticals, Inc.,
1180 Veterans Boulevard, South San Francisco, Califor-
nia 94080 (US). SHAW, Simon; c/o Rigel Pharmaceu-
ticals, Inc., 1180 Veterans Boulevard, South San Francis-
co, California 94080 (US). TAYLOR, Vanessa; c/o Rigel
Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San
Francisco, California 94080 (US). YU, Jiaxin; c/o Rigel
Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San
Francisco, California 94080 (US).

(74) Agent: LENTZ, Nelsen L. et al.; Eli Lilly and Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: RIPIK INHIBITORS



(57) Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition. (I)



WO 2022/005898 A1